AB Science: AB Science will participate in the Biomed Forum investors conference

PRESS RELEASEAB SCIENCE WILL PARTICIPATE IN THE BIOMED FORUM INVESTORS CONFERENCEParis, 22 january 2024, 7pm CETAB Science SA (Euronext - FR0010557264 - AB) announced that its management team will participate in the upcoming edition of the Biomed Forum, a conference for institutional investors. Organized by AllInvest Securities, this event will take place on February 4, 2025, in Paris.About AB ScienceFounded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a class of targeted proteins whose action are key in signaling pathways within cells. Our programs target only diseases with high unmet medical needs, often lethal with short term survival or rare or refractory to previous line of treatment.AB Science has developed a proprietary portfolio of molecules and the Company's lead compound, masitinib, ...Full story available on Benzinga.com